Amid questions about access to remdesivir, Gilead Sciences ( GILD ) is pursuing several steps to ensure the medicine is supplied to countries beyond the U.S ., STAT says. The drug maker indicated plans to issue voluntary licenses with "leading chemical and pharmaceutical" manufacturers to produce remdesivir for Europe, Asia, and the developing world through 2022. Similarly, negotiations are under way to issue licenses to several generic drug makers in India and Pakistan in order to supply the drug to developing countries.